Lessons learned from 2 years of influenza vaccinations in the UK and USA during the COVID-19 pandemic as respiratory viruses return.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
    • Publication Information:
      Publication: 2015- : Philadelphia, PA : Taylor & Francis
      Original Publication: Austin, Tex. : Landes Bioscience
    • Subject Terms:
      COVID-19*/epidemiology ; COVID-19*/prevention & control ; Influenza, Human*/epidemiology ; Influenza, Human*/prevention & control ; Viruses* ; Influenza Vaccines*; Humans ; Pandemics/prevention & control ; COVID-19 Vaccines ; Vaccination ; United Kingdom/epidemiology
    • Abstract:
      During the COVID-19 pandemic, immunization programs for other respiratory infections, notably influenza continued worldwide but attracted less public or political attention than COVID-19 vaccinations. Due to non-pharmaceutical intervention measures the global influenza burden decreased substantially; but with lifting of restrictions a rebound in other respiratory virus pathogens is both plausible and likely. This article discusses lessons identified from the UK and USA, and provides recommendations for future influenza vaccination programs in light of emerging data from the southern hemisphere and the need for harmonization with COVID-19 vaccination, focusing on operational delivery and messaging to practitioners and the public.
    • References:
      J Infect. 2021 Jan;82(1):1-35. (PMID: 33278399)
      Sci Rep. 2019 Jan 9;9(1):1. (PMID: 30626917)
      Sci Transl Med. 2013 Jun 26;5(191):191ra84. (PMID: 23803706)
      Pediatr Transplant. 2021 Aug;25(5):e14025. (PMID: 33904211)
      Vaccine. 2009 Aug 21;27 Suppl 3:C9-C14. (PMID: 19683658)
      Lancet. 2021 Dec 18;398(10318):2277-2287. (PMID: 34774197)
      Am J Health Syst Pharm. 2021 May 6;78(10):838-839. (PMID: 33954418)
      Science. 2021 Jun 4;372(6546):1043-1044. (PMID: 34083477)
      Lancet. 2022 Apr 16;399(10334):1463-1464. (PMID: 35344735)
      Nature. 2006 Jul 27;442(7101):448-52. (PMID: 16642006)
      Am J Transplant. 2020 Dec;20(12):3681-3685. (PMID: 33264506)
      Wellcome Open Res. 2020 Apr 2;5:59. (PMID: 32529040)
    • Contributed Indexing:
      Keywords: COVID-19; co-administration; flu campaign; flu vaccination campaign; influenza; northern hemisphere; public health; southern hemisphere; vaccination; vaccine; vaccine program
    • Accession Number:
      0 (COVID-19 Vaccines)
      0 (Influenza Vaccines)
    • Publication Date:
      Date Created: 20220926 Date Completed: 20221216 Latest Revision: 20221221
    • Publication Date:
      20231215
    • Accession Number:
      PMC9746353
    • Accession Number:
      10.1080/21645515.2022.2125754
    • Accession Number:
      36162068